Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma
NCT ID: NCT01387724
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients with newly diagnosed neuroblastoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Young Patients With Neuroblastoma
NCT01169376
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
NCT01493830
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Biomarkers in Samples From Young Patients With Neuroblastoma
NCT01358604
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma
NCT01553448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the expression of neuropeptide Y (NPY) and its receptors (Rs) in human neuroblastoma (NB) tissues.
* Determine whether BDNF/TrkB and TrkAIII stimulate expression of NPY and its Rs.
* Determine whether NPY mediates BDNF- and TrkAIII-induced NB proliferation and survival.
* Determine neurotrophins' angiogenic actions.
* Identify factors released from NB cells upon NPY stimulation (proteomics).
* Determine whether NPY upregulates expression of the identified proteins in NB and their Rs in endothelial cells (ECs).
* Test whether inhibition of the identified pathways reduces angiogenic activity of NB-conditioned media.
* Determine the mechanisms of NYP actions and signaling pathways.
* Test whether blocking NPY-Y2/Y5 pathway reduces NB growth and vascularization in vivo.
OUTLINE: Archived tumor tissue and serum samples are analyzed for neuropeptide Y and its receptors (Y1, Y2, and Y5) expression, neuroblastoma prognostic factors (MYCN, TrkA, TrkAIII, TrkB, BDNF, and NGF), and angiogenic markers by real-time PCR, IHC, ELISA, radioimmunoassay (RIA), mitogenic assay, caspase 3/7 activity assay, western blots, liquid chromatography, tandem mass spectrometry, proteomic assays, and other assays. Results are then analyzed and compared with patients' clinical data, including stage of disease, its phenotype, prognostic markers, age and gender, and response to treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA analysis
polymerase chain reaction
protein expression analysis
proteomic profiling
western blotting
enzyme-linked immunosorbent assay
immunohistochemistry staining method
laboratory biomarker analysis
liquid chromatography
mass spectrometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Children with newly diagnosed neuroblastoma or ganglioneuroblastoma
* Samples from the Children's Oncology Group (COG) from patients enrolled in clinical trials in institutions in the USA, Canada, and Australia
* Paraffin-embedded tumor specimens, RNA isolated from tumor tissues, and patient serum must be available
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
1 Year
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joanna Kitlinska, PhD
Role: PRINCIPAL_INVESTIGATOR
Lombardi Comprehensive Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ANBL11B1
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02862
Identifier Type: REGISTRY
Identifier Source: secondary_id
ANBL11B1
Identifier Type: OTHER
Identifier Source: secondary_id
ANBL11B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.